Cellectar Biosciences, Inc. (NASDAQ: CLRB) is developing agents to detect, treat and monitor a broad spectrum of cancers. With the ability to attach imaging and therapeutic agents to its proprietary delivery platform – a novel phospholipid ether (PLEs) platform technology … Continue reading →

Protea Biosciences Group, Inc. (OTC: PRGB) is a provider of innovative bioanalytical solutions to the pharmaceutical and life science industries. The company applies its proprietary technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules, which are … Continue reading →

Matinas BioPharma Holdings, Inc. (OTC: MTNB) is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections. The company’s lead anti-infective product candidates, MAT2203 and MAT2501, … Continue reading →

Neuralstem, Inc.’s (NASDAQ: CUR) patented technology enables the commercial-scale production of multiple types of central nervous system (CNS) stem cells, which are being developed as potential therapies for many CNS diseases and conditions. The company has completed phase Ia and … Continue reading →

Citius Pharmaceuticals, Inc. (OTC: CTXR) is a pharmaceutical company developing and commercializing therapeutic products for large and growing markets. Citius uses approved drugs with substantial safety and efficacy data in an effort to reduce the risks associated with pharmaceutical product … Continue reading →

Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. The proprietary Cytori Cell Therapy is under evaluation in … Continue reading →

Antisense Therapeutics Ltd. (OTC: ATHJF) is an Australian pharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics. One of Antisense Therapeutics’ fundamental strategies is acquiring access to state of the art antisense … Continue reading →

ContraVir Pharmaceuticals (NASDAQ: CTRV) is developing targeted antiviral therapies with two drug candidates in clinical studies. The first drug candidate, FV-100, is now in phase 3 trials. It is being developed for the treatment of herpes zoster, or shingles, and … Continue reading →

Aytu BioScience, Inc. (OTC: AYTU) is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. Aytu is initially concentrating on prostate cancer, male sexual dysfunction and male infertility and plans to expand into … Continue reading →